Overview of QL Biopharm's Abstract Presentation
QL Biopharmaceutical Co., Ltd. is thrilled to announce exciting developments regarding its lead drug candidate, ZT002. This groundbreaking ultra long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) is gaining attention in the battle against obesity. An important abstract highlighting the promising results from a two-part phase 1c study has been accepted for presentation at the upcoming European Association for the Study of Diabetes (EASD) Annual Meeting in Madrid.
Insights into ZT002's Clinical Study
Designed for easy monthly subcutaneous administration, ZT002 aims to set a new standard in obesity treatment. In a recent phase 1c study, which was randomized and placebo-controlled, 28 patients with obesity participated, revealing that ZT002 not only exhibited a favorable safety profile but also resulted in significant weight loss and notable improvements in cardiometabolic health.
Commentary from Leadership
Dr. Zhang Xujia, the esteemed Founder and CEO of QL Biopharm, shared his excitement about ZT002's potential, stating, "The emerging profile of ZT002 holds great promise as a new standard of care for patients living with obesity. We anticipate that it will simplify obesity treatment while effectively addressing weight management and type 2 diabetes needs." His remarks underscore the company's commitment to enhancing health outcomes for patients.
Presentation Details for EASD Annual Meeting
Here are the details for the poster presentation at the EASD Annual Meeting 2024:
Title and Session Information
Title: ZT002, a novel ultra long-acting GLP-1 receptor agonist in adults with overweight or obesity: a randomized, placebo-controlled, multiple ascending dose phase 1c study
Session: OP 25 Incretin receptor agonists: better and better
Date and Time
Date and Time: Thursday, 12 September 2024, 11:15 - 11:30 CEST
Presenter's Background
Presenter: Linong Ji, MD, a distinguished Professor of Medicine at Peking University People's Hospital, will lead this important session.
Venue and Abstract Number
Location: Madrid Hall
Abstract Number: 147
Exploring QL Biopharm's Mission
QL Biopharm is dedicated to developing cutting-edge peptide therapeutics aimed at addressing metabolic diseases. With a focus on innovative biopharmaceuticals and a proprietary manufacturing process utilizing E. coli, the company is committed to providing effective therapeutic solutions. ZT002 is at the forefront of these efforts, currently progressing into phase 2 studies for obesity while also investigating its effects on type 2 diabetes.
Company Portfolio Expansion
Alongside the advancements of ZT002, QL Biopharm is actively developing a variety of preclinical assets targeting multiple metabolic conditions. Their robust biosimilar semaglutide program is also making significant strides and is currently in phase 3 trials. The leadership team, comprised of industry veterans experienced in peptide manufacturing and metabolic disease therapeutics, strengthens the foundation of the company.
Engagement with the EASD Community
The EASD Annual Meeting is an important event for the scientific community focused on diabetes and metabolic research. Since its inception, the European Association for the Study of Diabetes (EASD) has prioritized advancing research and sharing knowledge within the diabetes field. Attending this conference allows QL Biopharm to showcase their innovative solutions and connect with peers in the industry.
Learn More About the EASD
The EASD is a highly regarded organization, established in 1965, with a mission to promote research and apply findings for the improvement of diabetes care. It plays a crucial role in the global diabetes research community.
Contact Information and Additional Resources
If you're interested in learning more about QL Biopharm and its pioneering initiatives, you can find additional information on their official website: QL Biopharm Website.
Frequently Asked Questions
What is ZT002 designed for?
ZT002 is an ultra long-acting GLP-1 receptor agonist aimed at managing obesity and related cardiometabolic conditions.
When and where will the EASD presentation occur?
The presentation is scheduled for 12 September 2024, in Madrid during the EASD Annual Meeting.
Who is presenting the abstract for ZT002?
Linong Ji, MD, a prominent expert in medicine, will present the abstract.
What phase of study is ZT002 currently in?
ZT002 is currently in phase 2 studies for obesity and phase 1 studies for type 2 diabetes.
How does QL Biopharm contribute to metabolic disease treatment?
QL Biopharm is focused on developing innovative peptide therapeutics and has a diverse portfolio targeting various metabolic diseases.
